When was Menten founded?

Menten was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Menten located?

Menten is headquartered in San Francisco, United States.

Who is the current CEO of Menten?

Hans Melo of Menten. They have also founded 1 company.

How many employees does Menten have?

As of May 31, 2026, the latest employee count at Menten is 19.

Is Menten a funded company?

Menten is a funded company, having raised a total of $4.15M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 18, 2020.

When was the latest funding round of Menten?

Menten's latest funding was a $***** Seed round on Jun 30, 2020, with participation from 2 investors. Its primary sector is Generative AI. In United States, the Generative AI sector has seen $252B in funding in 2026 to date.

Where does Menten rank among its competitors?

Menten ranks 30th amongst 202 active competitors, of which 60 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Algorithmiq, which secured $21.2M in May, 2026.

Who are the top competitors of Menten?

Menten's top competitors include Seer, Biognosys and ProteinQure. Among them, Algorithmiq secured the most recent funding round in May, 2026.

Menten - 2026 Company Profile, Team, Funding & Competitors

Menten is a seed company based in San Francisco (United States), founded in 2018 by Tamás Görbe, Vikram Mulligan and Hans Melo. It operates as a Developer of peptides using AI technology. Menten has raised $4.15M in funding from investors like Y Combinator, Khosla Ventures and Uncork Capital. The company has 202 active competitors, including 60 funded and 15 that have exited. Its top competitors include companies like Seer, Biognosys and ProteinQure.

Company Details

Menten AI is a developer of a platform for protein designing. The platform uses machine learning and quantum computing to design proteins based on requirements such as protein therapeutics and biocatalysis. The services offered by the company are rational peptide design and enzyme optimization.

Website: menten.ai
Social
Email ID: *****@menten.ai

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Seed

Total Funding

$4.15M in 2 rounds

Latest Funding Round

Seed, Jun 30, 2020, $*****

Investors

Y Combinator & 7 more

Ranked

30^th among 202 active competitors

Employee Count

19 as on May 31, 2026

Similar Companies

Innovaccer & 2536 more

View Menten's full profile

Menten has raised a total funding of $4.15M over 2 rounds. Its first funding round was on Mar 18, 2020. Its latest funding round was a Seed round on Jun 30, 2020 for $*****. 2 investors participated in its latest round. Menten has 8 institutional investors.

Here is the list of recent funding rounds of Menten:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2020	4623730	Seed	1582583	8015254	2460341	9792122
Mar 18, 2020	5759711	Seed	1830127	6507349	Y Combinator	4818059

Access funding benchmarks and valuations. Sign up today!

View details of Menten's funding rounds and investors

The founders of Menten are Tamás Görbe, Vikram Mulligan and Hans Melo. Hans Melo is the CEO of Menten.

Here are the details of Menten's key team members:

Tamás Görbe: COO & Co-Founder of Menten.
Vikram Mulligan: Co-Founder & CTO of Menten.
Contact Info: 1 email address
Hans Melo: Co-Founder & CEO of Menten.
Contact Info: 1 email address

View details of Menten's Founder profiles and Board Members

Menten's employee count trend

Menten has 19 employees as of May 26. Here is Menten's employee count trend over the years:

Uncover Menten's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Menten include Seer, Biognosys and ProteinQure. Here is the list of Top 10 competitors of Menten, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Redalpine & 6 others	63/100
3rd	ProteinQure 2017, Toronto (Canada), Series A	Provider of computational protein drug design platform	$15M	Felicis Ventures, Government of Canada & 9 others	49/100
4th	Peptris 2019, Bengaluru (India), Series A	Provider of AI-based proteomic data analysis software for drug discovery	$9.17M	Speciale Invest, Indian Angel Network Fund ... & 46 others	60/100
5th	Peptone 2016, Amsterdam (Netherlands), Series A	Provider of an AI based protein analysis platform for research and development	$42.5M	Bessemer Venture Partners, F-Prime Capital ... & 6 others	60/100
6th	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	Fifty Years, Y Combinator & 11 others	60/100
7th	Kuano Technologies 2020, London (United Kingdom), Seed	Provider of AI and quantum services for molecular design	$3.63M	Mercia, Ascension Ventures & 16 others	59/100
8th	Unnatural Products 2016, Santa Cruz (United States), Series B	Developer of computational biology techniques platform to engineer peptides for undruggable targets	$83M	Merck Global Health Innovation Fund, Artis Ventures ... & 17 others	58/100
9th	Algorithmiq 2020, Helsinki (Finland), Series B	Developer of quantum algorithms for chemistry and life science applications	$42.4M	United Ventures, Inventure & 12 others	57/100
10th	Atavistik 2021, Cambridge (United States), Series B	Developer of allosteric therapeutics for precision oncology and rare diseases	$260M	The Column Group, Nextech Invest & 3 others	57/100
30th	Menten 2018, San Francisco (United States), Seed	Developer of peptides using AI technology	$4.15M	Khosla Ventures, Y Combinator & 6 others	44/100